Literature DB >> 9395896

Fibrinolytic response to venous occlusion in patients with homozygous sickle cell disease.

B Nsiri1, N Gritli, C Mazigh, E Ghazouani, S Fattoum, S Machghoul.   

Abstract

The fibrinolytic potential was evaluated in 37 patients with homozygous sickle cell disease and compared to a control group of 30 age- and sex-matched healthy volunteers. In all individuals, the euglobulin clot lysis time and plasma antigen levels of t-Pa and PAI-1 were measured before and after venous occlusion (v.o) for 10 min. The global fibrinolytic activity was normal in 4 patients (good responders to v.o), while it was decreased in 33 patients (poor responders to v.o). Among the latter, 22 patients had significantly increased baseline levels of PAI-1 Ag (82.6 +/- 27.5 ng/ml, p < 0.001) and a normal release of t-Pa Ag after v.o. In contrast, 11 patients had basal values of PAI-1 Ag comparable to those in controls with a defective release of t-Pa Ag after v.o (11.4 +/- 5.2 ng/ml, p < 0.01). These data provide evidence for reduced fibrinolytic capacity resulting from either increased basal levels of PAI-1 or defective release of t-PA.

Entities:  

Mesh:

Year:  1997        PMID: 9395896     DOI: 10.1007/s00282-997-0229-7

Source DB:  PubMed          Journal:  Hematol Cell Ther        ISSN: 1269-3286


  11 in total

Review 1.  Physiological responses of sickle cell trait carriers during exercise.

Authors:  Philippe Connes; Harvey Reid; Marie-Dominique Hardy-Dessources; Errol Morrison; Olivier Hue
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

2.  Placenta growth factor (PlGF), a novel inducer of plasminogen activator inhibitor-1 (PAI-1) in sickle cell disease (SCD).

Authors:  Nitin Patel; Nambirajan Sundaram; Mingyan Yang; Catherine Madigan; Vijay K Kalra; Punam Malik
Journal:  J Biol Chem       Date:  2010-03-29       Impact factor: 5.157

3.  Role of the coagulation system in the pathogenesis of sickle cell disease.

Authors:  Md Nasimuzzaman; Punam Malik
Journal:  Blood Adv       Date:  2019-10-22

4.  Involvement of miR-30c and miR-301a in immediate induction of plasminogen activator inhibitor-1 by placental growth factor in human pulmonary endothelial cells.

Authors:  Nitin Patel; Stanley M Tahara; Punam Malik; Vijay K Kalra
Journal:  Biochem J       Date:  2011-03-15       Impact factor: 3.857

5.  Endothelial dysfunction biomarkers in sickle cell disease: is there a role for ADMA and PAI-1?

Authors:  Suellen Rodrigues Martins; Sílvia Letícia de Oliveira Toledo; Aislander Junio da Silva; Fernanda Santos Mendes; Marina Mendes de Oliveira; Leticia Gonçalves Resende Ferreira; Luci Maria Sant'Ana Dusse; Maria das Graças Carvalho; Danyelle Romana Alves Rios; Patrícia Nessralla Alpoim; Melina de Barros Pinheiro
Journal:  Ann Hematol       Date:  2021-10-19       Impact factor: 3.673

Review 6.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

Review 7.  How I diagnose and treat venous thromboembolism in sickle cell disease.

Authors:  Arun S Shet; Ted Wun
Journal:  Blood       Date:  2018-05-15       Impact factor: 22.113

8.  Peroxisome proliferator-activated receptor-α-mediated transcription of miR-301a and miR-454 and their host gene SKA2 regulates endothelin-1 and PAI-1 expression in sickle cell disease.

Authors:  Caryn S Gonsalves; Chen Li; Punam Malik; Stanley M Tahara; Vijay K Kalra
Journal:  Biosci Rep       Date:  2015-10-12       Impact factor: 3.840

Review 9.  The Worst Things in Life are Free: The Role of Free Heme in Sickle Cell Disease.

Authors:  Oluwabukola T Gbotosho; Maria G Kapetanaki; Gregory J Kato
Journal:  Front Immunol       Date:  2021-01-27       Impact factor: 7.561

10.  Hydroxyurea improves nitric oxide bioavailability in humanized sickle cell mice.

Authors:  Crystal M Taylor; Malgorzata Kasztan; Randee Sedaka; Patrick A Molina; Luke S Dunaway; Jennifer S Pollock; David M Pollock
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-02-24       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.